Guardant Health, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Unaudited Condensed Consolidated Financial Statements for Guardant Health, Inc. (GH) for the quarterly period ended March 31, 2026. Guardant Health is a precision oncology company focused on blood and tissue tests, real-world data, and AI analytics for cancer screening, monitoring, and treatment selection. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $301.7 million | $203.5 million |
| Net Loss | $(112.1) million | $(95.2) million |
| Loss Per Share (Basic & Diluted) | $(0.85) | $(0.77) |
| Operating Cash Flow | $(65.6) million | $(62.7) million |
| Cash, Equivalents & Marketable Securities | $1.10 billion | $803.9 million |
| Convertible Senior Notes (Net Carrying) | $1.50 billion | $1.50 billion |
| Stock-Based Compensation | $47.6 million | $37.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48% year-over-year, driven primarily by a 633% surge in Screening revenue ($41.6M vs. $5.7M) due to increased Shield test volume and reimbursement. Oncology revenue grew 36% to $205.0M, and Biopharma/Data revenue grew 17% to $53.0M.
- Expense Increases: Sales and marketing expenses rose 62% to $169.1M, attributed to commercial infrastructure expansion and marketing for Shield and oncology products. General and administrative expenses increased 23% to $57.9M, largely due to legal costs and stock-based compensation.
- Liquidity Position: Cash and cash equivalents increased significantly to $989.3M from $378.2M at year-end 2025, supported by net proceeds from investing activities ($699.4M) driven by the sale of marketable securities.
- Debt Status: The 2031 Convertible Senior Notes became convertible at the option of holders for the quarter ended June 30, 2026, as the stock price exceeded 130% of the conversion price. No conversion notices were received as of May 1, 2026.
Outlook, Risks, and Contingencies
- Legal Proceedings:
- TwinStrand/UW: A jury verdict of $83.4M in damages remains pending post-trial motions and appeals. The USPTO recently rejected all claims of the '631 Patent as invalid, while the '127 Patent is under further review.
- Natera: The company secured a $292.5M jury verdict for false advertising. The court affirmed a total damages award of $287.0M and granted injunctive relief.
- Tempus: The company successfully had a patent infringement lawsuit dismissed with prejudice. A separate false advertising dispute remains ongoing with a trial set for September 2027.
- Government Investigation: The company received a Civil Investigative Demand (CID) from the U.S. Attorney for the Southern District of Florida regarding billing to federally funded health insurance programs.
- Regulatory & Product: The FDA granted Breakthrough Device designation to the Shield Multi-Cancer Detection (MCD) test. The company is conducting the SOLAR study for Shield and the SHIELD LUNG study for lung cancer screening.
- Liquidity Outlook: Management believes current cash, equivalents, and marketable securities ($1.2B) are sufficient to meet requirements for more than 12 months.
Investor Verification Checklist
- Verify the status of the TwinStrand/UW patent litigation and the impact of the USPTO's rejection of the '631 Patent claims on the $83.4M liability.
- Monitor the 2031 Convertible Notes conversion activity, as they are currently convertible at the holder's option through June 30, 2026.
- Assess the sustainability of Screening revenue growth (Shield test) given the heavy reliance on Medicare and commercial payer reimbursement rates.
- Review the outcome of the False Claims Act investigation initiated by the U.S. Attorney for the Southern District of Florida.
- Track the cash burn rate relative to the $1.2B liquidity position, noting the continued negative operating cash flow of $65.6M for the quarter.